Alcoholic liver disease (ALD) comprises a clinical-histologic spectrum including fatty liver, alcoholic hepatitis (AH), and cirrhosis with its complications. Most patients are diagnosed at advanced stages and data on the prevalence and profi le of patients with early disease are limited. Diagnosis of ALD requires documentation of chronic heavy alcohol use and exclusion of other causes of liver disease. Prolonged abstinence is the most effective strategy to prevent disease progression. AH presents with rapid onset or worsening of jaundice, and in severe cases may transition to acute on chronic liver failure when the risk for mortality, depending on the number of extra-hepatic organ failures, may be as high as 20-50% at 1 month. Corticosteroids provide short-term survival benefi t in about half of treated patients with severe AH and long-term mortality is related to severity of underlying liver disease and is dependent on abstinence from alcohol. General measures in patients hospitalized with ALD include inpatient management of liver disease complications, management of alcohol withdrawal syndrome, surveillance for infections and early effective antibiotic therapy, nutritional supplementation, and treatment of the underlying alcohol-use disorder. Liver transplantation, a defi nitive treatment option in patients with advanced alcoholic cirrhosis, may also be considered in selected patients with AH cases, who do not respond to medical therapy. There is a clinical unmet need to develop more effective and safer therapies for patients with ALD. Am J Gastroenterol 2018; 113:175-194; doi: 10.1038/ajg.2017 
INTRODUCTION
Alcoholic liver disease (ALD) is one of the main causes of chronic liver disease worldwide and accounts for up to 48% of cirrhosisassociated deaths in the United States ( 1 ) . Alcohol is also a frequent co-factor in patients with other type of liver disease such as hepatitis C virus (HCV) infection where it accelerates hepatic fi brosis ( 2 ) . Owing to various susceptibility factors, individuals with long-term heavy alcohol use remain at risk for advanced liver disease with alcoholic steatohepatitis (ASH), cirrhosis, and hepatocellular carcinoma (HCC) ( 3 ) . Most patients with ALD present for medical care aft er they have developed jaundice or complications of cirrhosis ( 4 ) . Identifi cation of ALD in the primary-care setting at an early stage and subsequent behavioral interventions should thus be encouraged. Compared with the recent advances in viral hepatitis, few pharmacological advances have been made in the management of patients with ALD. To date, the most eff ective therapy to attenuate the clinical course of ALD and even reverse liver damage is prolonged alcohol abstinence ( 5, 6 ) . Given its high prevalence and economic burden, ALD is receiving increasing attention by health authorities, research funding organizations, and the liver academic community. Nevertheless, novel non-invasive tools to diagnose ALD at early stages and promising pharmacological approaches for alcoholic hepatitis (AH) are still needed. Finally, recent studies suggest that early liver transplantation (LT) can be successfully performed in highly selected patients with AH.
Th e authors were invited by the Board of Trustees and Practice Parameters Committee of the American College of Gastroenterology, to develop this practice guideline document on the management of patients with ALD.
Key concepts on ALD and specifi c recommendations have been developed for specialists in liver disease, gastroenterologists, and primary care providers, to aid them in the management of ALD patients. Recommendations based on Population Intervention Comparison Outcome format/Grading of Recommendations Assessment, Development, and Evaluation analysis are in Table 1 . Th ese recommendations and guidelines should be tailored to individual patients and circumstances in routine clinical practice. Key concepts and recommendations based on author expert opinion and review of literature are in Table 2 .
To develop these guidelines, a search was performed on the Ovid search platform: Epub Ahead of Print, In-Process and Other NonIndexed Citations, Ovid MEDLINE (R) Daily and Ovid MEDLINE (R), EBM Reviews Cochrane Central Registry of Controlled Trials, EMBASE, and PsycInfo for the period 1980 through July 2016. A combination of database-specifi c subject headings (e.g., MEDLINE Liver Diseases and Alcoholic) and text words (Alcohol* (truncated) within three words of liver, or hepat* (truncation) or cirrho* (truncation)) in association with LT (subject's headings plus text words). Th e results were downloaded from each database into EndNote X7 and duplicates removed. To evaluate the level of evidence and strength of recommendations, we used the Grading of Recommendations Assessment, Development, and Evaluation system, as suggested by the American College of Gastroenterology Practice Parameters Committee. Th e strength of recommendation is graded as strong or conditional as a consensus among the authors, considering the weight of desirable and undesirable eff ects of intervention. Th e level of evidence was determined independently of the authors and designated as high, moderate, low, and very low, considering the confi dence in the eff ect estimate based on current literature.
EPIDEMIOLOGY AND DISEASE BURDEN
Alcohol-use disorder (AUD) is one of the main causes of preventable disease and liver disease-associated mortality in the United States and worldwide. A recent report from the World Health Organization indicates that 3.3 million deaths (6% of all global deaths) are attributable to alcohol use, and that alcohol abuse is a risk factor in about 50% of cases of cirrhosis ( 1 ) . Approximately 1 in 12 adults have AUD defi ned as consumption of >3 drinks per day in males and >2 drinks per day in females, or binge drinking (defi ned by the National Institute of Alcoholism and Alcohol Abuse as >5 drinks in males and >4 drinks in females, consumed over 2 h period) ( 7 ) . In the United States, one drink is defi ned as a beverage containing about 14 g of alcohol, which is present in 12 ounces of beer (5% weight/volume) or 5 ounces of wine (8-10% weight/volume), or 1.5 ounces of hard liquor (40-45% weight/volume) ( 7 ) . Economic costs due to AUD (249 billion USD per year) are increasing. An estimated 88,000 people (~62,000 men and 26,000 women) die from alcohol-related causes annually, making alcohol the fourth leading preventable cause of death in the United States ( 8 ) . Apart from ALD, accidents or violence are other common causes of death among adult people abusing alcohol. In 2014, alcohol-impaired driving fatalities accounted for 9,967 deaths in the United States (31% of overall driving fatalities) ( 1 ) .
Th e association between alcohol and liver-related mortality is strongly supported by data showing a linear relationship between the standard liver death rate and overall alcohol consumption in many countries ( 9, 10 ) . Importantly, drinking patterns such as heavy episodic drinking vs. heavy daily use and the type of alcohol consumed may not independently predict the alcohol-attributable fraction of cirrhosis ( 11 ) . However, designation of countries by moderate or heavy daily drinking most clearly demonstrates the weight of alcohol on the cirrhosis burden ( 10 ) . Th e disease burden of alcohol is rapidly increasing in Asian countries such as China, Korea, and India. Th ere are also regional diff erences in Europe between Eastern and Western Europe, likely to be due to implementation of policy measures leading to decrease in alcohol use in many areas of Western Europe. on drinking in public places and on use of alcohol as gift s or in advertisements, and stricter legal action for driving under infl uence of alcohol. Th ese measures have been implemented primarily in Europe and have resulted in reducing the disease burden and consumption of alcohol. In the United States, strict alcohol policy Eff ective alcohol policy measures have been shown to reduce alcohol mortality, including ALD-related mortality ( 10, 12 ) . Cost eff ective measures include increase in taxes on sales of alcohol drinks, minimum sale price for alcohol, raising the legal age for buying alcohol, low level interventions from clinicians, ban 12. Systemic infl ammatory response syndrome (SIRS) at admission predisposes to acute kidney injury and multi-organ failure, which are associated with a poor prognosis. Physicians should take appropriate measures to prevent renal injury, such as avoidance of nephrotoxic drugs, judicious use of diuretics, and low threshold for expanding circulating blood volume with albumin or saline infusions 13. Infections are common in AH patients and comprehensive infectious screen is recommended as part of routine work-up of these patients. The development of bacterial infections during hospitalization is associated with poor prognosis 14. Response to treatment with corticosteroids should be determined at 7 days using the Lille score. Treatment should be discontinued among nonresponders to therapy, defi ned as those with a Lille score >0. 45 15. Patients non-responsive to corticosteroids, ineligible for early LT, and with multiple organ failures, may be considered for palliative therapy Liver transplantation in alcoholic liver disease Liver transplantation for alcoholic cirrhosis 16 . Physicians should consider LT while formulating a management plan for patients with end-stage ALD 17. The decision on LT evaluation should not be based solely on minimum 6 months of alcohol abstinence, and other criteria should be taken into consideration 18. Patients too sick to complete rehabilitation therapy may be considered for transplantation via exception pathway dependent on individual center policy and the patient's profi le. These patients can complete rehabilitation therapy after transplantation 19. Transplant recipients should be screened at each visit for use of alcohol and other substances especially tobacco and cannabis. Among recidivists, alcohol use should be quantifi ed to identify harmful use 20. Immunosuppression should be optimized to use lowest possible dose needed to prevent graft rejection. Use of sirolimus or everolimus may be considered over other immunosuppression drugs environments, especially alcohol taxes, were associated with lower alcoholic cirrhosis mortality rates ( 12 ) . Alcohol abuse or alcohol dependence is not synonymous with clinically important ALD, as only about 10-20% of chronic heavy drinkers develop severe forms such as AH or cirrhosis ( 13 ) . According to the National Institute of Alcoholism and Alcohol Abuse Surveillance Report on mortality in 2013, cirrhosis was the 12th leading cause of death in the United States, with about half of cirrhosis-related deaths being due to alcohol ( 8 ) . Th e crude death rate from cirrhosis due to any etiology was 12.0 deaths per 100,000 population, whereas the rate from alcohol-related cirrhosis was 5.7, representing an increase of 3.4% and 1.8% from 2012, respectively ( 1 ) . Th e WHO aims to reduce the death rate from ALD to below 3.2/100,000 population ( 1 ). Th ese fi gures become more relevant considering that ALD receives only about 5% of the research attention in the fi eld of hepatology ( 14 ) . As only about 10-20% of individuals with chronic heavy alcohol use develop advanced liver disease and cirrhosis, other disease modifi ers and cofactors, such as behavioral, environmental, and genetic factors, possibly have a role. Th ere is a clear dose relationship between the amount of alcohol intake and the likelihood of developing ALD; yet, extensive individual variability exists. Females are at risk for ALD at a lower daily intake of alcohol, probably due to higher body fat component and lower gastric alcohol dehydrogenase activity ( 15 ) . Th e impact of drinking patterns (i.e., binge drinking and drinking outside meals) and the type of beverage (wine vs. beer vs. liquors) is not well known and deserves large epidemiological studies. Th e general assumption that binge drinking favors the development of AH has not been proven in recent studies ( 11 ) . Obesity is one of most important environmental risk factor determining the risk of cirrhosis in heavy drinkers ( 16 ) . Heavy drinkers who are overweight for at least 10 years have a twofold risk of developing cirrhosis. Interestingly, several studies indicate that caff eine intake protects against cirrhosis in heavy drinkers ( 17 ) . Th e coexistence of chronic hepatitis B or HCV infection leads to an acceleration of liver injury, with more frequent and faster development of cirrhosis and its complications including HCC ( 2 ) . Iron accumulation, which is a common fi nding in advanced ALD, has also been associated with hepatic fi brosis in ALD and increased mortality in alcoholic cirrhosis ( 18, 19 ) . Cigarette smoking is common among alcoholic patients. It exacerbates the eff ects of alcohol in inducing severe ALD and favors development of HCC among patients with alcoholic cirrhosis ( 3, 20 ) . Once alcoholic cirrhosis develops, the risk for hepatic decompensation increases, especially among patients who continue to drink. In a Danish population-based study, which included 446 patients with alcoholic cirrhosis, the risk of developing ascites, variceal bleeding, or hepatic encephalopathy was ~25% aft er 1 year and 50% aft er 5 years ( 21 ) . With abstinence, the expected 5-year transplant-free survival rate following development of hepatic decompensation is 60% vs. 30% for those who continued to drink alcohol ( 22 ) .
ENVIRONMENTAL AND GENETIC DETERMINANTS
Genetic factors infl uence the susceptibility for advanced ALD. Monozygotic twins have a higher concordance rate for alcohol-related cirrhosis than dizygotic twins ( 23 ) . Genetic factors may infl uence susceptibility to alcohol consumption or predisposition to development of ALD among those with AUD. Genes infl uencing the susceptibility for alcoholism include modifi ers of neurotransmission such as γ -amino butyric acid and modifi ers of alcohol metabolism such as alcoholic dehydrogenase and acetaldehyde dehydrogenase enzymes ( 24 ) . Th e polymorphisms in these genes may be involved in an individual's susceptibility to alcoholism, with wide allelic variation between diff erent ethnic groups, but their role in the progression of ALD remains controversial. Th e second group of genes modifi es the natural history of ALD through diff erent mechanisms. Small candidate gene studies initially suggested a role for polymorphisms in genes encoding infl ammatory mediators, endotoxin response and oxidative stress. However, larger studies including a recent genome-wide association study revealed that patatin like phospholipase domain containing protein 3, may be the main genetic determinant of risk for and severity of ALD ( 25, 26 ) . Phospholipase domain containing protein 3 is closely related with lipid metabolism and is also a risk factor for non-alcoholic fatty liver disease and HCC ( 26 ) . Th e allele that negatively impacts disease progression (i.e., rs738409) is more frequent within the Hispanic population, which is particularly sensitive to fatty liver diseases ( 25 ) .
DISEASE SPECTRUM OF ALCOHOLIC LIVER DISEASE
ALD comprises a broad spectrum of diseases ranging from asymptomatic or early ALD (defi ned as fatty liver or alcoholic steatosis), to ASH and advanced ALD, (defi ned as AH, cirrhosis and its complications such as ascites, portal hypertension-related bleeding, hepatic encephalopathy, and HCC) ( Figure 1 ) . Th e clinical course of ALD is infl uenced by alcohol abstinence ( 5, 6 ) . Patients can regain a compensated status aft er initial hepatic decompensation if they stop drinking. Notably, some patients rapidly gain weight aft er they stop drinking, increasing their risk for developing nonalcoholic fatty liver disease. As there is no specifi c biomarker for the diagnosis of ALD, diagnosis requires excluding other liver diseases in a patient with heavy alcohol use.
Early alcoholic liver disease
Key concepts and statements 1 . Liver function tests and ultrasound examination should be performed among patients with harmful alcohol use and/or AUD.
heavy drinkers and may be seen within 2 weeks of heavy and regular alcohol ingestion. Hepatic steatosis resolves rapidly following complete abstinence ( 27 ) . Th e majority of patients with simple alcoholic steatosis are asymptomatic, but nausea, anorexia, and vomiting may be present ( 28 ) . Th e impact of simple alcoholic steatosis is not well known and is probably a benign condition. With continued excessive alcohol ingestion, approximately one-third of patients with steatosis have histological evidence of hepatic infl ammation (sometimes termed ASH) ( 29 ) . ASH, a term sometimes used to describe the histological features in AH, is diagnosed in patients with fatty liver disease when hepatic 2 . Liver biopsy is not routinely recommended for diagnosis of alcoholic fatty liver disease. However, liver biopsy and noninvasive tools of fi brosis may be considered for diagnosis of steatohepatitis and/or liver fi brosis.
Alcoholic fatty liver disease is diagnosed in a patient with AUD with hepatic steatosis on ultrasound and/or elevation in liver enzymes (aspartate aminotransferase (AST)>alanine aminotransferase (ALT)), serum bilirubin<3 mg/dL, and the absence of other causes of liver disease. Alcoholic fatty liver or simple steatosis, which is usually macro vesicular develops in ~90% of infl ammation/damage or fi brosis is present on liver biopsy ( Figure 2 ) . Unfortunately, about half of the patients with seemingly early disease may already have advanced fi brosis or cirrhosis on liver biopsy ( 5 ) . Of interest, patients with alcohol withdrawal syndrome (AWS) may have a higher prevalence of infl ammation on liver biopsy than do patients without withdrawal syndrome ( 29 ) .
Physical examination of patients with alcoholic fatty liver usually demonstrates only mildly tender hepatomegaly which rapidly resolves with abstinence. AST and ALT elevations are minimal (with AST typically greater than ALT) and γ -glutamyl transpeptidase may be elevated, but the serum bilirubin and International Normalized Ratio (INR) are typically normal. Th e diagnosis of hepatic steatosis is based on imaging (ultrasound or magnetic resonance) and a liver biopsy is not routinely required nor recommended for diagnosis.
A proportion of patients with evidence of steatohepatitis on liver biopsy develop hepatic fi brosis (20-40%) and cirrhosis (8-20%) . Th e risk of cirrhosis is increased in patients with steatohepatitis on biopsy as compared with patients with simple steatosis. It is important to emphasize that currently steatohepatitis can be diagnosed only on liver biopsy; there are no signs, symptoms, or biochemical tests that allow the confi dent diagnosis of steatohepatitis. In fact, one-third of patients with asymptomatic forms of ASH have signifi cant liver fi brosis and the presence of advanced fi brosis determines the long-term outcome. Th ere are few programs for early detection of ASH in primary-care centers and addiction centers. Th erefore, the prevalence of ASH and fi brosis among patients with AUD is not well known. Although awaiting further studies, the use of non-invasive tests of fi brosis (i.e., serum markers or elastography) may be useful in patients with AUD and abnormal liver tests.
Alcoholic hepatitis and cirrhosis
Th e true prevalence of AH is not well known, as its presence is commonly overlooked in patients with decompensated ALD. In one study, using the National Inpatient database, AH contributed to 0.8% of all hospitalizations in the United States, with ~325,000 hospital admissions in 2010 ( 30 ) . Th e clinical picture of AH is characterized by jaundice and is associated with risk for liver-related complications. AH can occur in any stage of liver disease and up to 80% of patients with severe AH (model for end-stage disease (MELD) score >20 and/or discriminant function (DF) ≥32) may have underlying cirrhosis. Th e population burden of alcoholic cirrhosis is underestimated and not clearly known, and the odds of alcoholic cirrhosis are higher in patients who have been hospitalized for alcoholism related problems ( 31 ) . Patients with severe AH are hospitalized for treatment and, in addition, can have complications of cirrhosis and sepsis.
DIAGNOSIS OF ALCOHOLIC-USE DISORDER

Recommendation
. Patients with heavy alcohol use (>drinks per day in men
and >2 drinks in women) for >5 years) should be counseled that they are at an increased risk for liver disease. (Strong recommendation, low level of evidence)
Key concept and statement
. Th e Alcohol Use Disorders Inventory Test (AUDIT) is a validated tool for identifying patients with alcohol abuse and dependence
Adjudicating alcohol as an etiology of liver disease depends upon diagnosis of AUD and excluding other causes of liver disease. Th ere are no defi nitive laboratory tests for diagnosis of liver disease related to alcohol use. Compared with non-alcoholic fatty liver disease, those with ALD oft en present late with advanced liver disease and its complications ( 4 ) . Data are needed on the role of non-invasive tools such as transient elastography among patients presenting with early ALD, such as fatty liver or minor derangement in transaminases.
Detailed history on alcohol consumption to identify AUD is important. As patients oft en underreport alcohol intake, questionnaires can be complemented by information from relatives (if appropriate) or by objective measures (e.g., physical signs of chronic alcohol use), tests suggestive of alcohol abuse (i.e., elevated blood alcohol, γ -glutamyl transpeptidase or urinary ethyl glucuronide elevation), or liver biopsy showing signs of alcohol-induced liver damage. Th e primary screening tool to detect alcohol abuse and dependence is AUDIT, which has high sensitivity and specifi city in clinical settings. AUDIT is a 10-item questionnaire, which has been validated as a clinical tool for the accurate detection of alcohol consumption ( 32 ) . With a score of 0-40, an AUDIT score of >8 constitutes AUD, or alcohol abuse, and a score of >20 qualifi es for diagnosis of alcohol dependence ( Figure 2 ). As the completion of AUDIT can be time consuming for both physicians and patients, a shorter version or AUDIT-c has been developed and found to be as accurate as an initial screening test for diagnosing AUD ( 33 ) . Th is brief version should be employed in the primarycare setting to identify patients with AUD. When approaching patients with suspected ALD, the provider should also ask the patient for the following: type of alcoholic beverage (i.e., beer, wine, and spirits/liquors), pattern of drinking (i.e., daily, with or without meals, increase during the weekend), the frequency of binge drinking, and date of the last drink. It is also important to identify previous attempts made by the patient to stop drinking (i.e., Alcoholics Anonymous meetings, previous treatment by addiction counselors, alcohol detoxifi cation hospitalizations, etc.).
As the self-reported alcohol use is oft en inaccurate, the use of alcohol biomarkers can be useful to diagnose alcohol consumption. Of the biochemical tests, mean corpuscular volume, aminotransferases, and γ -glutamyl transferase are sensitive tests, but lack specifi city in patients with cirrhosis ( 34 ) . Carbohydratedefi cient transferrin combined with γ -glutamyl transferase has sensitivity of about 75-90%. However, the levels of carbohydratedefi cient transferrin may be confounded with increasing disease severity and active smoking ( 35 ) . Newer biomarkers using metabolites of alcohol such as ethyl glucuronide can reveal alcohol use up to 3-4 days aft er the last alcohol drink ( 36 ) . However, due to its high sensitivity, it can yield false-positive results with exposure to alcohol containing medications and hand sanitizers containing small amounts of ethanol ( 37 ) . Measurement of ethyl 5 . Medical treatment of ALD should be ideally performed by multidisciplinary teams including alcohol addiction specialists.
Th erapies for treatment of AUD aim at achieving complete alcohol abstinence with use of pharmacological therapy and behavioral therapy with motivational interviewing. Patients actively drinking are at a high risk of severe AWS during inpatient alcohol detoxifi cation. Obstacles to completing addiction therapies include the following: lack of specialized care, refusal by the patient, lack of insurance coverage, patient too sick to attend therapy sessions, and transportation ( 40 ) . Recognizing these obstacles will help the clinician to address these with the patient as basis of providing optimal management.
Pharmacological therapies. Many pharmacological agents have been used for treatment of AUD including disulfi ram, acamprosate, gabapentin, naltrexone, topiramate, sertraline, and baclofen ( 41 ) . Of these, only baclofen, a γ -amino butyric acid-B receptor agonist has been found to be safe in patients with ALD and cirrhosis. Its effi cacy is shown with increase in abstinence rates ( 42 ) . Baclofen can be started in a dose of 5 mg three times a day and the dose can be increased at a 3-5 days interval based on patient tolerance to a maximum dose of 15 mg three times a day. Considering its excellent safety profi le, even among patients with advanced liver disease and AH, patients on baclofen therapy can be monitored by hepatologists or addiction specialists.
Non-pharmacological therapies. Th e other major approach to induce or to maintain alcohol abstinence in patients with ALD is behavioral interventions such as motivational enhancement therapy, cognitive behavioral therapy, motivational interviewing, supportive therapy, and psychoeducation ( 43 ) . Motivational interviewing, the most commonly used intervention, is a technique that aims to be both non-judgmental and non-confrontational. It attempts to increase a patient's awareness of the potential problems caused, consequences experienced, and risks faced because of excessive alcohol use. Essential components of a motivational approach are an empathic attitude and a collaborative approach that respects the patients' autonomy ( 40, 44 ) . A brief intervention should have at least the components defi ned in the fi ve "A" model: ask about use, advice to quit or reduce, assess willingness, assist to quit or reduce and arrange follow-up. Cognitive behavior therapy is a structured goal-directed form of psychotherapy in which patients learn how their thought processes contribute to their behavior.
Psychologic interventions can be diffi cult in patients with hepatic encephalopathy, cognitive impairment, or poor performance status ( 40 ) . Moreover, patients with end-stage liver disease have frequent hospitalizations that preclude attendance at psychosocial interventions. No psychosocial intervention has been consistently shown to be successful in maintaining abstinence in patients with ALD. Rather, an integrated therapy with cognitive behavioral therapy and medical care appear to reduce recidivism. Th ere is a clear need for clinical trials combining psychosocial and pharmacological interventions in ALD patients with AUD. glucuronide in hair samples can detect alcohol use for a longer period of up to 1 month ( 38 ) . Urine ethyl glucuronide and phosphatidyl ethanol are commercially available for use in routine clinical practice ( 36 ) .
Screening of psychosocial conditions
It is important to identify concomitant psychosomatic disorders in individuals with AUD, as simultaneous treatment of these disorders is crucial in maintaining abstinence. Individuals with AUD have high prevalence of anxiety, aff ective disorders, psychosis, and posttraumatic stress disorder. In other situations, patients use excessive drinking to cope with untreated chronic pain, or sleeping disorders. Th ey may also have a history of sexual abuse, violence, social isolation, and history of driving while impaired. Patients with AUD have a higher risk of developing other addictions, including nicotine, opioids, and benzodiazepines; polysubstance users are diffi cult to manage and should be systematically referred to specialized treatment. Two of the commonly overlooked issues in a busy clinic practice of physicians are masked depression and anxiety disorder in these individuals, and these factors increase the risk for relapse to alcohol use and failure of counseling or detoxifi cation therapy sessions. A simple screening tool for assessing for underlying depression is a Patient Health Questionnaire (PHQ)-2 questionnaire, which includes two questions (each scored from 0-3 depending on severity) for symptoms over the last 2 weeks for: (a) little interest or pleasure in doing things? and (b) feeling down, depressed, or hopeless? A similar questionnaire for generalized anxiety disorder or Generalized Anxiety Disorder (GAD) includes two questions (each scored from 0 to 3) for symptoms over the last 2 weeks for: (a) feeling nervous, anxious, or edgy? and (b) not being able to stop or control worrying ( 39 )? On each of these tools, a score of 3 or more constitutes a positive response and need for further intervention.
MANAGEMENT OF ALCOHOLIC LIVER DISEASE
Patients with ALD are suff ering from two diff erent disorders, namely AUD and liver disease. Hence, the treatment should involve integrated management targeting both the disorders. Key concepts and statements 4 . Alcohol consumption is a major determinant of disease progression and long-term outcome of patients with ALD. Complete abstinence from alcohol consumption is the cornerstone in the management of every spectrum of ALD.
Management of alcohol-use disorder
Management of alcohol withdrawal
Key concepts and statements 6 . AWS should be stratifi ed and managed as per Clinical Institute Withdrawal Assessment for Alcohol protocol ( 45-49 ).
7 . In patients with severe AWS and ALD, benzodiazepines are the treatment of choice.
AWS is a common condition aff ecting alcohol-dependent patients who abruptly discontinue or markedly decrease alcohol consumption. Light or moderate AWS usually develops within 6-24 h aft er the last drink and symptoms may include nausea/vomiting, hypertension, tachycardia, tremors, hyperrefl exia, irritability, anxiety, and headache. Th ese symptoms may progress to more severe forms of AWS, characterized by delirium tremens, generalized seizures, coma, and even cardiac arrest and death. Older patients are at greater risk for delirium tremens.
Patients with moderate or severe alcohol withdrawal should be closely monitored in an intensive care unit (ICU), where vital signs, volume status, and neurological function are monitored on a regular basis. Severity scores for AWS such as the Clinical Institute Withdrawal Assessment for Alcohol score are useful in the management of patients, although they have not been validated in patients with severe ALD and a symptom-triggered approach is preferred ( 45, 46 ) .
Benzodiazepines are the most commonly used drugs to treat AWS. Long-acting benzodiazepines (e.g., diazepam and chlordiazepoxide) predominantly protect against seizures and delirium; short and intermediate-acting benzodiazepines (e.g., lorazepam and oxazepam) are safer for patients with poor liver function. Patients with AWS and concomitant hepatic encephalopathy should be treated for both the conditions. Of note, high-dose benzodiazepines may precipitate and worsen hepatic encephalopathy; thus, careful monitoring and titration is critical for optimal outcomes. Given the side eff ects of benzodiazepines in patients with advanced liver disease and the potential for abuse in an addictive population, other drugs such as baclofen, clonidine, gabapentin, and topiramate have been proposed to treat AWS in patients with ALD including alcoholic cirrhosis. However, the effi cacy and safety of these substances in patients with AH is unknown and therefore prospective studies are required. A promising approach is to use baclofen to prevent and treat moderate AWS fi rst, and continue the medication to prevent alcohol relapse.
Management of liver disease
Alcoholic cirrhosis . It is important to assess the nutritional status of ALD patients as malnutrition is oft en present in these patients (see section on nutritional supplementation for details). Patients with alcoholic cirrhosis should be screened for varices with upper gastrointestinal endoscopy ( 50 ) . Th ese patients are also at an increased risk of developing HCC, with a life-time risk of about 3-10% and an annual risk of about 1%. Obesity and cigarette smoking are risk factors for HCC in patients with alcoholic cirrhosis. Patients with alcoholic cirrhosis should undergo screening with ultrasound examination with or without α -fetoprotein testing every 6 months for HCC ( 51 ) . Immunization against hepatitis A and B, pneumococcal pneumonia and infl uenza is also recommended (Center for Disease Control and Prevention link on vaccinations).
Patients with decompensated cirrhosis are managed as for any patient with cirrhosis as described below.
Ascites. A diagnostic paracentesis is warranted to rule out spontaneous bacterial peritonitis. A therapeutic paracentesis is carried out as required for symptom relief of tense ascites. Management of ascites and hepatorenal syndrome should follow established guidelines. In addition to antibiotics, albumin 1.5 g/kg is recommended on day 1 and 1 g/kg on day 3 in the presence of spontaneous bacterial peritonitis ( 52 ) .
Hepatic encephalopathy. Th is is managed as per prevailing guidelines and includes lactulose and rifaximin therapy, as well as control of infection. Cerebral damage, malnutrition, and infections among patients with alcohol-related cirrhosis and continued alcohol use may lower the threshold in development of hepatic encephalopathy. However, other causes of altered mental status should be screened for, especially among patients who present with atypical neuro-psychiatric features that warrant questioning the diagnosis of hepatic encephalopathy or AWS. For example, seizures, focal neurological defi cits, severe headache, and encephalopathy refractory to all measures should point towards an alternate cause for altered consciousness such as stroke, subdural hematoma, drug overdose, meningitis, and fungal infections of the central nervous system. A drug screen is recommended and in selected patients imaging of the head and cerebral spinal fl uid studies may be required ( 53 ) .
Variceal bleeding. Management of the acute variceal bleeding episode involves pharmacological therapy with available vasoactive agents (terlipressin or octreotide), antibiotics, and endoscopic therapy. Endoscopy should ideally be carried out at least 30 min aft er initiation of vasoactive therapy ( 54 ) .
ALCOHOLIC HEPATITIS
Diagnosis of alcoholic hepatitis
Key concepts and statements 8 . Clinical diagnosis of AH is determined in a patient with rapid development or worsening of jaundice and liver-related complications, with serum total bilirubin >3 mg/dL; ALT and AST elevated >1.5 times the upper limit of normal but <400 U/L with the AST/ALT ratio >1.5; documentation of persistent heavy alcohol use until 8 weeks before onset of symptoms; and exclusion of other liver diseases 9 . In patients with suspected AH, a transjugular liver biopsy is recommended when the clinical diagnosis is confounded by another liver disease etiology or there is uncertainty on alcohol consumption history 10 . Patients with severe AH should preferably be hospitalized for management Liver biopsy. One area of controversy is the need for a liver biopsy to confi rm the diagnosis of AH. In a recent NIH-sponsored consensus meeting of investigators, it was proposed to defi ne AH as defi nite, probable, or possible based on clinical features, presence of confounding serology for other liver disease etiology, and liver histology ( 57 ) ( Table 3 and Figure 3 ). Defi nite AH was categorized as a compatible clinical diagnosis along with liver biopsy confi rming the existence of criteria of AH; probable AH was defi ned as classic clinical syndrome, as defi ned above in the absence of confounding serology for another disease; possible AH was defi ned as clinically suspicious for AH, presence of confounding factors such as ischemic hepatitis, possible drug-induced liver injury, serology positive for another liver disease etiology, or uncertain alcohol use. It was proposed that patients with possible AH should undergo liver biopsy to confi rm the diagnosis, especially if specifi c pharmacologic interventions are proposed. On the other hand, the diagnosis of probable AH may be associated with only a low rate of histologic misclassifi cation and therefore biopsy may not be essential in this population.
Characteristic histological fi ndings of AH include macro vesicular steatosis, lobular infi ltration of neutrophils with hepatocyte damage (Mallory-Denk bodies and/or ballooning), bilirubin stasis and liver fi brosis, which is typically described as peri cellular and sinusoidal ("chicken wire" appearance) ( 58 ) ( Figure 4 ). Th ese features are indistinguishable from non-ASH and the alcoholnon-ALD index (including body mass index, gender, AST, ALT, and mean cell volume of the red blood cells or mean corpuscular volume) can be helpful to distinguish the two in cases of unclear alcohol consumption ( 59 ) . Th e majority of AH patients have underlying macronodular cirrhosis, which is not easily distinguishable from other forms of cirrhosis. When cirrhosis is established, steatosis may be less prominent. On electron microscopic examination, megamitochondria may be observed. If liver biopsy is performed for diagnosis of AH, the fi ndings may also have prognostic value. For example, one recent study showed that presence of severe fi brosis, megamitochondria, degree of neutrophil infi ltration, and cholestasis could predict prognosis in patients with AH ( 60 ).
Prognostic scores and natural history
Many scoring systems have been developed to predict severity of AH. Th e Maddrey Discriminant Function is the most time tested and validated scoring system, with severe AH defi ned by Maddrey Discriminant Function ≥32 ( 61 ) . Retrospective and prospective analysis of this score indicates that Maddrey Discriminant Function ≥32 predicts a mortality rate of ~20-50% over 30 days ( 62 ) . Most clinical trials for AH have used this score based on its use in the original corticosteroid trials. A number of other scoring History. Clinical features of AH include non-specifi c constitutional symptoms such as fatigue but may also include symptoms attributable to advanced liver disease. Th e history of alcohol use needs to be carefully documented including the date of last drink. Collateral information from relatives about drinking patterns is oft en required to confi rm the history on alcohol consumption. Suspicion for AH should be high in a patient with recent onset or worsening of jaundice in the setting of chronic heavy alcohol use, which has been active until at least 8 weeks before presentation. History should also include previous admissions for AH, type, duration and amount of alcohol intake, previous alcohol counseling and/or detoxifi cation attempts, recent cocaine and other drug use, potential hepatotoxic drugs, gastrointestinal bleeding, duration of jaundice, and possible source of infection including urinary, pulmonary, cutaneous, and abdominal.
Physical examination. Many physical examination signs overlap with alcoholic cirrhosis refl ecting portal hypertension and complications of cirrhosis. Malnutrition of variable degree and sarcopenia is present in most patients with AH. Signs of chronic alcohol intake (e.g., Dupuytren contracture, rhinophyma, etc.), signs of chronic liver disease (spider angioma, palmar erythema, and jaundice), signs of portal hypertension (splenomegaly, ascites, and hepatic encephalopathy), and of alcohol withdrawal (tremors, tachycardia, agitation, seizures in severe AWS, or delirium tremens) may be present ( 55 ) . Features of systemic infl ammatory response syndrome (SIRS) may be present in these patients even in the absence of infection ( 56 ) . SIRS criteria include the presence of ≥2 of the following: heart rate >100 beats per minute, temperature >38 °C or <36 °C, respiratory rate >12 breaths per minute, and white blood cell count >12,000 or <4,000 mm.
In addition to SIRS criteria, tender hepatomegaly and occasionally, hepatic bruit may be present. A very careful search should be made for a source for potential infection or sepsis, including skin examination for signs of cellulitis and infection around venous lines.
Laboratory abnormalities. Specifi c laboratory abnormalities to diagnose AH include bilirubin >3 mg/dL; AST >50 but <400 IU/L, with AST/ALT ratio of >1.5. Th e severity of liver disease should also be documented by measuring the serum bilirubin, creatinine, INR, albumin, and electrolytes to calculate the MELD score, MELD sodium score, and Maddrey discriminate function scores (see section on prognosis and disease severity). As these patients have high risk for infection, diligent infectious work up should be performed including ascitic fl uid cell counts with cultures in patients with ascites, urine microscopic examination and cultures, chest X-ray, blood, and sputum cultures as clinically indicated. As SIRS features along with rapidly increasing jaundice may mimic cholangitis, it is prudent to exclude biliary obstruction. systems have also been validated and generally performed similar to the Maddrey score, including the MELD score, Age Bilirubin INR Creatinine (ABIC) score, and the Glasgow scale ( 62 ) . Th e MELD score is being increasingly used to assess severity of AH given its better accuracy, worldwide use in organ allocation, INR as standard in reporting prothrombin time, and incorporation of renal function and serum creatinine, which is a major determinant of outcomes in AH patients. A MELD score >20 has been proposed as defi ning severe AH with an ~20% mortality ( 63 ) . Lille score (a continuous score with a scale from 0 to 1) at 4-7 days of corticosteroids therapy can be used to assess the response to corticosteroids (Lille score <0.45) ( 64 ) . Most of these scores by themselves do not predict prognosis accurately aft er 90 days and are most predictive at 30 days. A number of other variables infl uence prognosis aft er 30-90 days, most notably the ability to maintain abstinence from alcohol or not ( 5, 6 ) . Recent studies have shown that combination use of MELD at baseline and Lille score at day 7 has best discrimination and calibration for 2-month and 6-month mortality ( 65 ) . In addition, serum lipopolysaccharide levels, SIRS criteria, and other serum markers may also serve as biomarkers of mortality ( 56 ).
Treatment of alcoholic hepatitis
General measures and supportive treatment: provided to all AH patients irrespective of disease severity. 13 . Infections are common in AH patients and a comprehensive infectious screen is recommended as part of routine work-up of these patients. Th e development of bacterial infections during hospitalization is associated with poor prognosis
Patients hospitalized with severe AH oft en have history of active heavy alcohol use and present with manifestations of the SIRS ( 56 ). Sepsis and malnutrition are common among this population ( 4 ). Ascites, variceal bleeding, and hepatic encephalopathy may also be present. In-patient management should therefore focus on alcohol withdrawal, nutritional supplementation, infections and sepsis, complications of cirrhosis and portal hypertension, and specifi c treatment of AH. Patients may also develop acute on chronic liver failure, which manifests with hepatic and extrahepatic organ failure requiring intensive care (see below).
Nutrition and fl uid replacement . Malnutrition and sarcopenia are common among hospitalized AH patients with negative impact on outcome (66) (67) (68) . Many randomized controlled studies have shown improvement in nutritional status, but with controversial data on survival benefi t with enteral supplementation (69) (70) (71) (72) (73) or parenteral supplementation. Although enteral supplementation in severe AH did not show survival benefi t in a recently reported randomized study, there were more deaths with daily caloric intake of <21.5 kcal/kg per day compared with higher intake of calories. Th e enteral route due to its low cost, safety, and lower risk for infections is the preferred route. Feeding tube can be safely placed in the presence of esophageal varices without active bleeding or who have not undergone recent endoscopic variceal banding ( 74 ) . Patients with severe AH need daily protein intake of 1.2 to 1.5 g/kg and caloric intake of 35 Kcal/kg. Zinc and other trace elements may need to be replaced. Th iamine and B complex vitamins need to be replaced. Albumin is preferred to crystalloid for volume replacement.
Intensive care. Th e patient may require transfer to the ICU in the presence of extrahepatic organ failure. Indications for transfer to the ICU include stage III or stage IV hepatic encephalopathy and the need for ventilation, respiratory failure, hemodynamic instability, and septic shock. Scoring systems to predict mortality in ICU patients include the SOFA score ( 75 ) and the CLIF SOFA score ( 76 ) . Th e North American Consortium for Study of End Stage Liver Disease-Acute on Chronic Liver Failure (NACSELD ACLF) score is the easiest to use-patients with two or more extra-hepatic organ failures, second infections, and higher MELD score are at greatest risk of mortality ( 77 ) .
Sepsis surveillance should be performed and broad-spectrum antibiotics should be administered before transfer to the ICU, or within one hour of admission. Th e choice of antibiotics depends on prevailing local antimicrobial resistance patterns. Piperacillintazobactam is generally the preferred drug used for sepsis, although vancomycin and meropenem may be considered in patients with penicillin hypersensitivity. As sepsis is diffi cult to diagnose in this group and about 40-50% of patients may be culture negative, there should be a low threshold for diagnosis of infection and initiation of antibiotic therapy. Diagnosis of infections in patients with AH and cirrhosis should be performed using standardized defi nitions and guidelines ( 78 ) . It is important to diff erentiate community acquired infections from nosocomial infections (onset aft er 48 h of admission to hospital) or healthcare-associated infections (within fi rst 48 h of admission in patients with hospitalization within past 6 months, clinic visit within past 30 days, or those residing in nursing homes), as the empiric antibiotics for nosocomial or healthcareassociated infections should cover broadly for multidrug resistant bacteria, and in select high-risk cases for atypical organisms and fungal infections.
Ulcer prophylaxis is recommended using proton pump inhibitors. Both proton pump inhibitors and H2 antagonists increase the risk of infections such as aspiration pneumonia and clostridium diffi cile, but decrease the risk of chemical pneumonitis and gastrointestinal bleeding. Proton pump inhibitors are superior to H2 antagonists for the prevention of gastrointestinal bleeding. Glucose control is targeted to levels <200 mg/dL and transfusion is required with the hemoglobin target of 7-8 g/dL.
Organ failure scores are used to determine severity of acute on chronic liver failure. Patients with renal failure and acute kidney injury should receive diligent care with the aim to identify and reverse precipitating factors and improve renal function. Renal replacement therapy is recommended in the presence of acute kidney injury in the presence of sepsis-associated acute tubular necrosis, or if the cause of acute kidney injury is unclear. In the presence of hepatorenal syndrome, a therapeutic trial of renal replacement therapy may be considered in patients who are potential liver transplant candidates. Patients requiring pulmonary support should receive low tidal volume to avoid lung injury. Vasoconstrictors and pressor may be needed to maintain mean blood pressure of >65 mm Hg.
Specifi c pharmacologic therapies. Pharmacological therapies examined for AH patients are listed in Table 4 . Response to treatment with corticosteroids should be determined at 7 days using the Lille score. Treatment should be discontinued among non-responders to therapy, defi ned as those with a Lille score >0.45
15 . Patients non-responsive to corticosteroids, ineligible for early LT, and with multiple organ failures may be considered for palliative therapy.
Corticosteroids. As the fi rst randomized controlled study to assess effi cacy of corticosteroids in the treatment of AH in 1971 ( 79 ), a total of 14 randomized studies (12 against placebo, 1 against enteral supplementation, and 1 against antioxidant cocktail) have reported confl icting data, likely to be due to variations on inclusion/exclusion criteria and the use of liver biopsy for confi rming the diagnosis of AH ( 61, (79) (80) (81) (82) (83) (84) (85) (86) (87) (88) (89) (90) . In a pooled analysis, using individual patient data from the fi ve largest randomized controlled studies (85) (86) (87) (88) 91 ) , corticosteroids provided survival benefi t at 28 days (80% vs. 66%, P <0.0001) in half of the patients ( 92 ) . Th e largest randomized placebo controlled multicenter study from the United Kingdom (the STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH) study) on 1,103 severe AH patients showed only a trend for mortality benefi t at 28 days with prednisolone, compared with patients receiving placebo (13.8% vs. 18%, P =0.056). A meta-analysis of randomized studies (including the STOPAH study) showed that corticosteroids were eff ective in reducing short-term mortality by 46%.
Prednisolone is preferred over prednisone, as the latter requires conversion to prednisolone, which may be impaired in patients with impaired liver synthetic function. Moreover, prednisone did not improve patient survival in a randomized clinical trial ( 89 ) . Prednisolone is used in a dose of 40 mg per day for a total duration of 4 weeks. Methylprednisolone 32 mg per day by intravenous route is used for patient unable to take oral medications. Th ere are no studies examining diff erent doses no diff erence in another study ( 116 ) . Pentoxifylline was not eff ective when examined as salvage option for steroid non-responders, ( 117 ) or as an adjuvant therapy to corticosteroids ( 118, 119 ) . In a meta-analysis of 10 randomized studies, pentoxifylline failed to show survival benefi t at 1 month, but was eff ective in reducing the occurrence of hepatorenal syndrome by 53% ( 120 ) . Th e exact mechanism of renal protection with pentoxifylline remains unclear. Th e STOPAH study showed no survival benefi t with pentoxifylline ( 90 ) . In a network meta-analysis of 22 studies including the STOPAH study, there was low-quality evidence for benefi t of pentoxifylline in reducing the short-term mortality at 28 days by 30% ( 121 ) . It is possible that subgroups of patients (i.e., kidney failure) with AH may benefi t from pentoxifylline, but this needs to be examined prospectively.
Tumor necrosis factor-α inhibitors . Based on pre-clinical efficacy and benefi cial eff ects in open label pilot studies (122) (123) (124) (125) , trials examining infl iximab and etanercept in the management of severe AH had to be terminated prematurely due to higher number of deaths in the treatment arm, with most deaths due to infections ( 126, 127 ) . Th e mechanisms of these fi ndings are speculated to be due to blocking the benefi cial eff ects of tumor necrosis factor on hepatic regeneration ( 128 ) .
Antioxidants . Oxidative stress is a major player in the pathogenesis of ALD and AH ( 129 ) . Antioxidant cocktails and vitamin E examined earlier have not shown benefi cial eff ects in the management of severe AH ( 88, 130, 131 ) . N-acetylcysteine infusion showed improved survival at 1 month, when used as an adjuvant to prednisolone in a multicenter randomized controlled study ( 132 ) . Th ere was no survival advantage with N -acetylcysteine at 3 or 6 months from presentation. A network meta-analysis comparing various pharmacological agents showed moderate quality evidence that combination of prednisolone and N -acetylcysteine provides best survival benefi t at 28 days with 85% risk reduction of death from AH ( 121 ) . However, more data on the effi cacy of N -acetylcysteine in severe AH patients are needed before recommending its routine use in practice.
Miscellaneous drugs. Hepatic regenerative capacity supported by bone marrow-derived stem cells and hepatic progenitor cells is a major determinant of the outcome of patient with AH ( 133, 134 ) . However, drugs targeting this pathway including insulin and glucagon ( 135, 136 ) , anabolic steroid, oxandrolone ( 137 ) , and propylthiouracil ( 138, 139 ) failed to demonstrate a mortality benefi t. Recently, the use of growth factors with granulocyte colony stimulating factor and erythropoietin have shown encouraging data in improving liver disease, reducing infectious complications, and patient survival ( 140, 141 ) . Molecular adsorbent recycling system safely improves liver disease, renal function, and portal hypertension, without any signifi cant improvement in survival ( 142 ) . Fecal transplantation has also been tested in eight subjects with contraindications to steroid therapy with encouraging results in a preliminary analyses ( 143 ) . Patients with ≥4 failed organs being treated in ICU, who are not candidates for LT, are unlikely to survive beyond 3-6 months. Continuing further intensive treatment in these patients may be futile ( Figure 3 ) ( 144 ). and durations of corticosteroid therapy. Response to therapy is determined at 1 week of therapy using the Lille score. About 50-60% of patients do not respond to steroids (Lille score>0.45) and these patients do not derive further benefi t from continuing steroids ( Figure 3 ) ( 64 ) . Recently, the Lille score at day 4 of corticosteroid therapy has been shown to be as accurate as day 7 Lille score in predicting the outcome and response to treatment, although this observation needs further validation studies ( 93 ) . Unpredictable response to corticosteroids combined with fear of adverse eff ects, especially risk of infections limit the use of these drugs in routine clinical practice, with only 25-45% providers using them as reported in two diff erent surveys ( 94, 95 ) . Th ere is a clear unmet need for development of safer eff ective pharmacological options for management of AH patients and for biomarkers to predict response to corticosteroids at the time of presentation (96) (97) (98) .
Active hepatitis B virus infection and active tuberculosis are contraindications for use of corticosteroids ( 99 ) . Although HCV infection may potentially worsen the outcome of AH patients ( 30, (100) (101) (102) , there are no data on whether 4 weeks of corticosteroid therapy will increase HCV replication or that HCV infection worsens the response to corticosteroids. Active infection or sepsis, uncontrolled diabetes mellitus, and gastrointestinal bleeding remain relative contraindications to the use of corticosteroids. In these situations, corticosteroids can be used once the contraindication has been reversed with appropriate therapy. For example, use of corticosteroids aft er adequate control of infection has been reported to provide similar benefi t as in uninfected patients ( 103 ) . However, development of infections remains a concern among patients treated with corticosteroids, as these drugs compromise the immune status of an individual, putting them at risk for infections ( 104 ) . In pooled data from 12 randomized studies comparing corticosteroids and placebo, infections during treatment occurred in about 20%, with steroid use associated with risk of fungal infections ( 105 ) . In one study comprising patients with high bacterial DNA levels (>18.5 pg/mL) enrolling in the STOPAH study, the use of prophylactic antibiotics improved patient survival in corticosteroids treated patients ( 106 ) . Th ere remains an unmet need to determine accurate biomarkers with a potential for earlier diagnosis of infections, and randomized studies exploring benefi t of antibiotics used as prophylaxis or as adjuvant to corticosteroids among patients with AH at high risk for development of infections ( 56 ) .
Pentoxifylline. A phosphodiesterase inhibitor, pentoxifylline inhibits tumor necrosis factor-α activity, one of the major cytokines speculated in the pathogenesis of AH ( 107, 108 ) . As the fi rst seminal study on the benefi t of pentoxifylline used as 400 mg 3 times a day ( 109 ), many other randomized studies have failed to show survival benefi t in severe AH patients (110) (111) (112) (113) . However, pentoxifylline has consistently shown benefi t in reducing the risk of renal injury and deaths from hepatorenal syndrome ( 109, 114 ) . Although pentoxifylline is known to inhibit tumor necrosis factor, levels of tumor necrosis factor did not change with pentoxifylline (PTX) in the reported seminal study ( 109 ) . Pentoxifylline compared with corticosteroids showed benefi t in one study ( 115 ) LT is a defi nitive therapy for patients with cirrhosis and endstage liver disease. Alcoholic cirrhosis is the third most common indication for LT aft er hepatitis C and non-alcoholic fatty liver disease. LT for alcohol related cirrhosis accounts for about 15% of all liver transplants in the United States and about 20% in Europe (145) (146) (147) . Similarly, of all the LT performed, about 10% and 6% are performed for HCV-infected drinkers in the United States and Europe, respectively (145) (146) (147) .
Referral for LT. Access to LT involves three steps: referral to a LT center, formal evaluation and listing, and fi nally receipt of LT. Although, barriers to receiving LT exist at every step, physicians may have bias against referral of patients with alcoholic cirrhosis for formal LT evaluation ( 148 ) . Subjective variables like patient age, physician empathy on alcoholism as a disease and not behavior, geographical area, race, amount and duration of alcohol use, and adherence to treatment are some of the barriers for referral of patients, who otherwise may be potential LT candidates (148) (149) (150) . Studies are needed to provide a basis for deriving guidelines using objective parameters on referral of these patients to a LT center. While evaluating an ALD patient for LT, specifi c issues as outlined below need to be considered.
Evaluation for comorbidities. Alcohol consumed on a longterm basis can damage other body organs such as the cardiovascular system (cardiomyopathy, hypertension, and chronic kidney disease), gastrointestinal system (chronic pancreatitis, diarrhea, malnutrition, and vitamin defi ciencies), nervous system (Wernicke's encephalopathy, seizures, dementia, and peripheral neuropathy), hematological system (macrocytosis and multifactorial anemia), musculoskeletal system (sarcopenia, deconditioning, and osteoporosis), and psychological system (psychiatric comorbidities and use of cigarette smoking and recreational drugs) (151) (152) (153) (154) . In one epidemiological study, either alcohol abuse or smoking was associated with a nearly two-fold increased risk for chronic kidney disease and this risk was about fi vefold when both factors were present ( 154 ) . Presence of any of these comorbidities in ALD patients should be assessed before transplantation since they can negatively impact posttransplant outcomes ( 150, 151 ) .
Evaluation for risk of recidivism. Relapse to alcohol use aft er LT (recidivism) is an important concern in any transplant recipient who had AUD before transplantation ( 155 ) . Most transplant centers require minimum of 6 months of abstinence before considering LT evaluation ( 150 ) . However, data on minimum 6 months of abstinence as a predictor of recidivism remain confl icting. Other predictors include younger age, social support, psychiatric comorbidities, polysubstance abuse, duration and amount of alcohol use, family history of alcoholism, and failed rehabilitation attempts ( 156, 157 ) . Many transplant centers utilize the Psychosocial Assessment of Candidacy for Transplantation scale to evaluate patients to stratify patients to low, intermediate and high risk for recidivism ( 34 ) . Patients at high risk for recidivism are particularly advised to go through therapy for alcoholism prior to LT ( 158 ) . Patients waiting on the transplant list should be monitored for alcohol consumption at every clinic visit, as about 17-30% of these patients may relapse to alcohol use ( 159, 160 ) .
Involvement of addiction specialists and incorporation of an addiction unit within the LT center is useful in reducing frequency of drinking and recidivism compared to referring these patients to an outside center for addiction therapy ( 161 ) . However, the patient's degree of illness and transportation issues may be signifi cant limiting factors in these patients' ability to complete therapy sessions ( 40 ) .
Posttransplant outcomes. Patient survival rates aft er LT for alcoholic cirrhosis at 1, 3, 5, and 10 years aft er LT are reported to be 84-89%, 78-83%, 73-79%, and 58-73%, respectively, which are better compared with transplants for HCV cirrhosis or for HCC, and similar to other indications for LT ( 145, 147 ) . Th ese excellent results are associated with improved feeling of physical and mental health, environment at home and at work, sexual relationship, and relationships within family and friends (162) (163) (164) . Although transplant recipients experience an improved quality of life within the fi rst year, this tends to decline over long-term with perception of poorer physical health ( 165 ) . Many transplant recipients resume employment and return to work, either full or part time.
It is important to emphasize that LT cures the liver disease, but not the underlying AUD ( 150 ) . Prevalence of recidivism varies from 10 to 60% across diff erent studies due to variations on defi nition of recidivism (any or harmful alcohol use) and on follow-up time aft er LT. In a pooled data from 50 studies on LT for alcoholic cirrhosis, annual incidence of recidivism was 5.7% and 2.5% for any alcohol use and for harmful use, respectively ( 166 ) . Recidivism is most likely to be reported aft er 2 years of LT with the majority of recidivists reporting intermittent use of alcohol ( 155, 167 ) . Patients with harmful use of alcohol aft er LT have 10-year survival rates 45-71%, compared with 75-93% among abstinent patients or those with occasional slips (168) (169) (170) (171) . Self-reported alcohol use is oft en unreliable ( 159, 172 ) , and biomarkers of alcohol consumption can help in identifying patients with ongoing alcohol consumption (please refer to the section on 'Diagnosis of AUD').
agents targeting mammalian target of rapamycin inhibitors such as sirolimus an everolimus, given their anti-tumor eff ects ( 181, 182 ) .
Recurrent alcoholic cirrhosis is reported in about 5% of all LT performed for alcoholic cirrhosis, with cumulative probability of 33-54% at 10 years aft er LT among recidivists ( 183, 184 ) . Survival of patients with recurrent cirrhosis is about 41 and 21% at 10 and 15 years aft er LT respectively, compared to similar survival rates of about 70 and 50% among abstainers ( 183 ) . Immunosuppression should be maintained at the lowest safe levels as with all patients who undergo a liver transplant; it is unclear whether everolimus or sirolimus are superior to calcineurin inhibitors among patients transplanted for alcoholic cirrhosis ( 185 ) .
Liver transplantation for alcoholic hepatitis
Recommendation
9 . LT may be considered for highly selected patients with severe AH (Strong recommendation, moderate level of evidence)
To minimize the risk of recidivism, most transplant centers require a minimum of 6 months of abstinence before considering LT for a patient with ALD. However, patients with severe AH not Th e limited data comparing outcomes of patients receiving LT for liver disease due to combined ALD and HCV infection with LT for alcoholic cirrhosis have shown confl icting fi ndings, likely due to variations on HCV treatment before LT and on data source (registry based vs. single-center chart review) (173) (174) (175) . Whether outcomes of transplant recipients of HCV infected drinkers will improve with the advent of newer potent and safer anti-HCV therapy, remains a testable hypothesis, yet to be answered.
Causes of posttransplant morbidity and mortality. Important causes of patient morbidity and mortality among transplant recipients for alcoholic cirrhosis are development of de-novo malignancy or cardiovascular complications. Compared with the general population, the risk of development of de-novo malignancy is about two-to threefold higher among transplant recipients for alcoholic cirrhosis, contributing to 20-40% of all deaths ( 176, 177 ) especially malignancies of the head and neck, pharynx, esophagus, and lung (176) (177) (178) (179) .
Th e risk for aero-digestive cancers is higher among transplant recipients with a history of smoking prior to LT and who continue to smoke aft er LT ( 179, 180 ) . Th e risk of malignancy may be also related to dose and type of immunosuppression. Compared with other immune-suppressing drugs, malignancy risk is lower with responding to medical therapy cannot aff ord to meet this requirement given their short-term mortality at 1 month from presentation as high as 50% ( 96 ) . Th e lack of eff ective rescue medical therapies for non-responders to prednisolone provides the rationale for considering early LT.
In a case controlled study, Mathurin et al. ( 186 ) transplanted highly selected patients with severe AH, who were non-responsive to corticosteroids and had a favorable psychosocial profi le. Patients receiving early LT for AH were compared with an historical cohort managed medically. Survival at 6 months of patients with early LT was dramatically improved (77% vs. 23%) ( 186 ) . Most of this benefi t was achieved within fi rst month, confi rming the utility of early LT in salvaging select AH patients who do not respond to corticosteroids. Further, recidivism was only reported in a minority of patients with salvage LT (<15%) ( 186 ) . Th e recidivism rate reported in this study was similar to historical data on self-reported annual recidivism rate in LT recipients for alcoholic cirrhosis ( 166 ) . In another study on analysis of national transplant database in the United States, patients receiving LT for listing diagnosis of AH compared with matched LT recipients for alcoholic cirrhosis had similar liver graft and patient survival at 5 years follow-up ( 187 ) . Data are also emerging from other centers reporting similar benefi ts of early LT in select severe AH patients (188) (189) (190) . As patients with AH are neither listed for urgent LT nor receive exception points, live donor LT is being performed in many Asian countries. Limited data on outcomes of living donor LT in AH patients are similar compared with LT using deceased donors ( 191 ) . In light of these emerging data, early LT as a defi nitive therapy is gaining momentum and acceptance within the transplant community, as well as the general public ( 190, 192 ) . LT for AH can salvage these sick AH patients at risk of death in their most productive life and consumes only 1.5-3% of the donor pool ( 186, 188, 190 ) .
Despite these encouraging data, there remain barriers at every level to use this treatment modality for AH. For example, in a recently reported survey, LT center directors in the US reported center protocol, socio-cultural issues, organ shortage, and insurance approval as barriers to LT in AH ( 190 ) . In this survey, there was agreement among the transplant centers on excellent psychosocial support and non-response to corticosteroids as criteria for patient selection. However, only 50% of LT centers were using all the fi ve criteria proposed in the study by Mathurin et al. ( 190 ) . Further, 1-year survival of 77% as reported in the prospective study is inferior to historic survival of over 90% aft er LT for alcoholic cirrhosis, with majority of deaths being due to invasive fungal infections ( 145, 186 ) . Patients with severe AH are prone to fungal infections, especially those who are non-responders to corticosteroids ( 105, 193 ) . Prospective multicenter studies are needed as basis for deriving guidelines for selection of AH patients for LT, antibiotic protocol for infection prevention in the perioperative period, and immunosuppression protocol on long-term follow-up of these patients.
CONCLUSIONS AND PROSPECTS
Alcohol use constitutes a huge economic and population burden in the United States and worldwide. Despite the known hepatotoxic eff ect of alcohol use, the fi eld lacks availability of eff ective safe pharmacotherapies for management of ALD patients. With growing interest of the research community and increasing funding from National Institute of Alcoholism and Alcohol Abuse and other organizations, the future holds promise for overcoming some of these urgent unmet clinical needs in this fi eld ( Table 5 ).
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